Request Information

Opal Biosciences Ltd

  • Life-threatening “superbugs” are driving the need for new anti-infective agents. Infections are becoming harder to treat and few new treatments are available. Opal Biosciences is an innovative player in infectious disease treatment, targeting human infection - a high growth, commercially attractive market segment.
  • Opal's commercial strategy is to licence or sell to a larger pharmaceutical company within 3 years. Opal Biosciences will proceed to an IPO on an appropriate stock exchange within 18 months to two years, subject to any alternate commercial transaction before then.